1 – 8 of 8
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Interleukin-1 receptor accessory protein (IL-1RAP) : A magic bullet candidate for immunotherapy of human malignancies
(
- Contribution to journal › Scientific review
- 2022
-
Mark
Modular design of synthetic receptors for programmed gene regulation in cell therapies
(
- Contribution to journal › Article
- 2021
-
Mark
Cell Fate Reprogramming in the Era of Cancer Immunotherapy
(
- Contribution to journal › Scientific review
-
Mark
The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo
(
- Contribution to journal › Article
- 2019
-
Mark
Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International Immunocancer Registry (ICIR)
(
- Contribution to journal › Article
-
Mark
Understanding and Modulating Immunity With Cell Reprogramming
(
- Contribution to journal › Scientific review
- 2015
-
Mark
TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression
(
- Contribution to journal › Article
- 2007
-
Mark
Clinical-scale generation of strongly CD83-expressing dendritic cells using extracorporeal photopheresis
(
- Contribution to journal › Article